	US 11,939,399 B2
	Synthetic peptide sp4 and use thereof
Wanqin Zhang, Feicheng (CN); Yintian Li, Feicheng (CN); Xuewen Ji, Feicheng (CN); and Limei Zhao, Feicheng (CN)
Assigned to TAIAN CITY QIHANG BIOTECHNOLOGY CO., Feicheng (CN)
Filed by TAIAN CITY QIHANG BIOTECHNOLOGY CO., Feicheng (CN)
Filed on Mar. 24, 2022, as Appl. No. 17/656,347.
Application 17/656,347 is a continuation of application No. 16/762,470, abandoned, previously published as PCT/CN2018/109931, filed on Oct. 12, 2018.
Claims priority of application No. 201810739279.3 (CN), filed on Jul. 6, 2018.
Prior Publication US 2022/0332761 A1, Oct. 20, 2022
Int. Cl. C07K 7/08 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 7/08 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01)]

12 Claims

1. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a composition, wherein the composition comprises a synthetic peptide sp4 consisting of an amino acid sequence of SEQ ID NO: 1, wherein the cancer is human osteosarcoma or human esophagus cancer.